'Tevimbra,' a type of immune checkpoint inhibitor, is becoming more widely available for prescription at general hospitals.

According to industry sources, BeiGene's PD-1 inhibitor Tevimbra (tislelizumab), which has applied for reimbursement for its esophageal cancer indication, has passed the drug committees (DC) of tertiary general hospitals, including Samsung Medical Center, Seoul National University Hospital, Seoul St. Mary's Hospital, and Asan Medical Center.

Tevimbra is a PD-1 inhibitory immune checkpoint inhibitor that demonstrated clinical usefulness as the second-line therapy for esophageal squamous cell carcinoma. It was approved in South Korea in November 2023.